Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Arch Neurol 65:1429-1433, Liang,B.A.,et al, 2008
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
Streamlined Hyeracute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression is Stroke Mimic
Stroke 47:1012-1017, Goyal, M.S.,et al, 2016
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Selecting Stroke Patients for Intra-Arterial Therapy
Neurol 78:755-761, Balucani,C. and Grotta,J.C., 2012
Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke
Stroke 42:1967-1970, Sarikaya, H.,et al, 2011
Neuroimaging in Acute Posterior Cerebral Artery Infarction
The Neurologist 14:170-180, Finelli,P.F., 2008
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1099-1100, 1100, Zivin,J.A., 2005
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1098-1099,1100, Schellinger,P.D. &Fiebach,J.B., 2005